Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Abstract:

:BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutations other than V600E are reported. Eligible patients with stage IIIC or IV melanoma and non-V600E BRAF mutations received vemurafenib (960 mg, twice daily). End points included investigator-assessed best overall response rate (primary), time to response, duration of response, progression-free survival, overall survival and safety. Planned (V600K vs. non-V600K mutations) subgroup analyses were carried out. Thirty-one patients were enrolled; 13 (42%) had V600K mutations and 18 (58%) had other mutations. Investigator-assessed confirmed that the best overall response rate was 23% (95% confidence interval=10-41%) in the overall population, and was similar between patients with V600K mutations (23%; 95% confidence interval=5-54%) versus other mutations (22%; 95% confidence interval=6-48%). Responses were observed in patients with V600K (n=3), V600E2 (n=1), V600R (n=1), L597S (n=1) and D594G (n=1) mutations. No new safety signals were reported. Vemurafenib showed activity in patients with advanced melanoma with rarer BRAF mutations.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Hallmeyer S,Gonzalez R,Lawson DH,Cranmer LD,Linette GP,Puzanov I,Taback B,Cowey CL,Ribas A,Daniels GA,Moore T,Gibney GT,Tawbi H,Whitman E,Lee G,Mun Y,Liu S,Hamid O

doi

10.1097/CMR.0000000000000398

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

585-590

issue

6

eissn

0960-8931

issn

1473-5636

pii

00008390-201712000-00008

journal_volume

27

pub_type

杂志文章,多中心研究
  • Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?

    abstract::Isolated limb perfusion (ILP) with melphalan is used to treat recurrent melanoma. This study aimed to develop a microdialysis technique for melphalan tissue concentration measurement during ILP. The effects of melphalan concentration (50-600 microg/ml), microdIalysis flow rate (0.55-17.5 microl/min), probe length (5-5...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Wu ZY,Smithers BM,Anderson C,Roberts MS

    更新日期:2000-02-01 00:00:00

  • Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.

    abstract::In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melano...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/CMR.0000000000000056

    authors: Bedikian AY,Garbe C,Conry R,Lebbe C,Grob JJ,Genasense Melanoma Study Group.

    更新日期:2014-06-01 00:00:00

  • Acral cutaneous melanoma in a Spanish Caucasian population.

    abstract::Acral lentiginous melanoma (ALM) is the most frequent type of cutaneous melanoma in the Asian and African populations, but the fourth distinct variant of cutaneous melanoma in the Caucasian population. Histological criteria and prognosis of ALM remain controversial. A retrospective study, showing epidemiological, clin...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3282f1d2b6

    authors: Avilés-Izquierdo JA,Longo-Imedio MI,Lázaro-Ochaita P

    更新日期:2010-06-25 00:00:00

  • Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

    abstract::Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-200404000-00016

    authors: Macripò G,Quaglino P,Caliendo V,Ronco AM,Soltani S,Giacone E,Pau S,Fierro MT,Bernengo MG

    更新日期:2004-04-01 00:00:00

  • Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.

    abstract::There is no general consensus regarding the optimal follow-up strategy for patients with melanoma. We sought to determine the utility and cost effectiveness of radiological restaging of patients with stage IIB-IIIC melanoma at the 3-year follow-up time point. A retrospective review of 210 patients diagnosed with stage...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283471086

    authors: DeRose ER,Pleet A,Wang W,Seery VJ,Lee MY,Renzi S,Sullivan RJ,Atkins MB

    更新日期:2011-08-01 00:00:00

  • F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.

    abstract::Metabolic imaging with F-18 fluorodeoxy-D-glucose positron emission tomography is one of the most sensitive and non-invasive techniques, and has proved useful in melanoma. We designed, in 2004, at the Institute Gustave Roussy, a prospective study to determine the value of F-18 fluorodeoxy-D-glucose positron emission t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32815c10b0

    authors: Maubec E,Lumbroso J,Masson F,Suciu V,Kolb F,Mamelle G,Cavalcanti A,Boitier F,Spatz A,Aupérin A,Leboulleux S,Avril MF

    更新日期:2007-06-01 00:00:00

  • Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases.

    abstract::Microsatellite instability (MSI) is caused by replication errors due to deficient DNA mismatch repair and has been associated with tumour progression in various types of cancer. Controversial results have been reported concerning the frequency and significance of MSI in malignant melanoma. In this study, the time of o...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200304000-00009

    authors: Palmieri G,Ascierto PA,Cossu A,Colombino M,Casula M,Botti G,Lissia A,Tanda F,Castello G

    更新日期:2003-04-01 00:00:00

  • Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.

    abstract::Mucosal melanoma of the nasal cavity and paranasal sinus is always associated with poor prognosis, and 5-year overall survival does not exceed 40%. Our study aimed to compare the intraoperative conditions and prognosis of different surgical techniques to determine the optimum surgical approach for patients with mucosa...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000516

    authors: Yin G,Guo W,Chen X,Huang Z

    更新日期:2019-02-01 00:00:00

  • Differential expression of heat shock protein 105 in melanoma and melanocytic naevi.

    abstract::The objective of this study is to assess the expression of heat shock protein 105 (HSP105) in melanoma and benign melanocytic lesions. The expression of HSP105 in 62 human melanoma samples--46 primary and 16 metastatic lesions--and 42 melanocytic naevi samples, was assessed by immunohistochemistry. Western blotting wa...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3282fe9a16

    authors: Muchemwa FC,Nakatsura T,Fukushima S,Nishimura Y,Kageshita T,Ihn H

    更新日期:2008-06-01 00:00:00

  • Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.

    abstract::Occasional reports indicated cytokeratin (CK) protein expression (mainly by immunohistochemistry) in malignant melanoma (MM) and suggested an association with unfavorable clinical parameters. However, the mRNA expression of CK and its clinicopathologic significance in MM has not been specifically evaluated. We investi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283252feb

    authors: Chen N,Gong J,Chen X,Xu M,Huang Y,Wang L,Geng N,Zhou Q

    更新日期:2009-04-01 00:00:00

  • Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy.

    abstract::In this study we investigated the antitumour effect and mechanism of action of cationic liposome-mediated murine interferon-beta (IFNbeta) gene therapy in mouse B16F1 melanoma cells in vitro and in vivo. Murine IFNbeta gene transfer by cationic liposome resulted in substantial growth inhibition of B16F1 melanoma cells...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200308000-00003

    authors: Ryuke Y,Mizuno M,Natsume A,Suzuki O,Nobayashi M,Kageshita T,Matsumoto K,Saida T,Yoshida J

    更新日期:2003-08-01 00:00:00

  • Immunosuppression and melanocyte proliferation.

    abstract::Melanocytes are pigmented cells derived from the neural crest; their proliferation is restrained by immune system. The eruption of nevi after an immunosuppressive condition is a peculiar phenomenon indicating that the immune system may play a major role in limiting proliferation of melanocytes. In this review, we anal...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0b013e328322fc20

    authors: Zattra E,Fortina AB,Bordignon M,Piaserico S,Alaibac M

    更新日期:2009-04-01 00:00:00

  • Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic applications of the marker.

    abstract::Melan-A is widely used in the diagnostics of human melanoma. The immunogenicity of this glycoprotein makes it a potential target in immunotherapy and several authors have suggested its potential as a prognostic factor. Up to now there has been no clear direct evidence of changes of Melan-A expression during the progre...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328303beac

    authors: Sztramska A,Dymerska D,Chwirot BW

    更新日期:2008-08-01 00:00:00

  • In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity.

    abstract::When cancer cells, including melanoma cells, are genetically altered to secrete cytokines, irradiated and injected into subjects, long-term antitumour immunity is induced. Optimally, existing melanomas induced to produce cytokines in vivo could stimulate this same immune response. Although in vivo electroporation enha...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200012000-00010

    authors: Heller L,Pottinger C,Jaroszeski MJ,Gilbert R,Heller R

    更新日期:2000-12-01 00:00:00

  • Pregnancy and the apoptotic pathway in experimental melanoma.

    abstract::Pregnancy-associated melanoma is defined as melanoma diagnosed during pregnancy or within 1 year of delivery. The association of pregnancy with melanoma is well known, but its underlying molecular mechanisms of association are poorly understood. The aim was to assess the expression of apoptosis-related genes in melano...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000452

    authors: Facina AS,Facina G,Guerreiro da Silva IDC,Corrêa SAA,Alexandre SM,Logullo ÂF,Hosomi JK,Nakamura MU

    更新日期:2018-08-01 00:00:00

  • BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

    abstract::Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000214

    authors: Sloot S,Zager JS,Kudchadkar RR,Messina JL,Benedict JJ,Gonzalez RJ,DeConti R,Turner LM,McCardle T,Smalley KS,Weber JS,Sondak VK,Gibney GT

    更新日期:2016-02-01 00:00:00

  • In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.

    abstract::The mechanism of action of fotemustine, a relatively new chloroethylnitrosourea, was evaluated in human melanoma cells in order to assess its potential as an agent for hyperthermic limb perfusion. Fotemustine was more toxic to O6-alkylguanine methyl transferase (AGT) deficient (Mer-) cells than Mer+ cells, implicating...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199802000-00012

    authors: Hayes MT,Bartley J,Parsons PG

    更新日期:1998-02-01 00:00:00

  • The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

    abstract::Recently, TROG 02.01 results showed that in stage III melanoma patients with nodal metastasis, adjuvant radiation to lymph node basin after nodal dissection improves lymph node field relapse without an overall survival (OS) benefit. However, this trial was neither designed nor powered to detect an OS difference. In th...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000292

    authors: Danish HH,Patel KR,Switchenko JM,Gillespie TW,Jhaveri J,Chowdhary M,Abugideiri M,Delman KA,Lawson DH,Khan MK

    更新日期:2016-12-01 00:00:00

  • Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.

    abstract::Malignant melanomas usually have an unfavourable prognosis and poor response to chemotherapy. Deregulation of cell proliferation, programmed cell death and intercellular interactions are among several important mechanisms that might lead to malignant transformation of melanocytes and melanoma progression. The S100A1, ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283350554

    authors: Sviatoha V,Tani E,Kleina R,Sperga M,Skoog L

    更新日期:2010-04-01 00:00:00

  • Lovastatin-induced apoptosis in human melanoma cell lines.

    abstract::The cholesterol-lowering medications, statins, inhibit cellular proliferation and induce apoptosis in an array of cancer cell lines, including melanoma. We investigated the apoptotic mechanism of lovastatin on human melanoma cell lines in vitro. The cytotoxicity of statins on multiple cell lines was examined by Cell T...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200504000-00001

    authors: Shellman YG,Ribble D,Miller L,Gendall J,Vanbuskirk K,Kelly D,Norris DA,Dellavalle RP

    更新日期:2005-04-01 00:00:00

  • Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

    abstract::The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine-dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine-dacarbazine toge...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0b013e328341445f

    authors: Bedikian AY,Johnson MM,Warneke CL,Papadopoulos NE,Kim KB,Hwu WJ,McIntyre S,Rohlfs M,Homsi J,Hwu P

    更新日期:2011-02-01 00:00:00

  • A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

    abstract::A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/CMR.0000000000000556

    authors: Block MS,Nevala WK,Pang YP,Allred JB,Strand C,Markovic SN

    更新日期:2019-08-01 00:00:00

  • The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?

    abstract::CD8 T-cell infiltration of metastatic melanoma may be a useful biomarker for prediction of prognosis and response to therapy. The heterogeneous distribution of CD8 T cells within a single tumor, and across different tumors within a single patient, may complicate quantification of infiltration. However, the impact of h...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000330

    authors: Obeid JM,Hu Y,Erdag G,Leick KM,Slingluff CL Jr

    更新日期:2017-06-01 00:00:00

  • A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.

    abstract::A 58-year-old man with indolent metastatic BRAF mutant melanoma presented with several days' history of progressive ataxia and dysdiadochokinesia. His PET/computed tomography restaging scan indicated two new fluorine-18-fluorodeoxyglucose-avid mesenteric lymph nodes. Meanwhile, his MRI brain and whole spine were withi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000264

    authors: Lee SF,Atkinson V

    更新日期:2016-08-01 00:00:00

  • Malignant melanoma and pregnancy.

    abstract::The occurrence of cancer in pregnant women is not a common phenomenon and the real incidence of malignant melanoma during this period is unknown. Many authors reported a poor prognosis in pregnant women with melanoma compared with non-pregnant women's tumour. Several retrospective reviews reported a worsened prognosis...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/01.cmr.0000232295.91536.09

    authors: Silipo V,De Simone P,Mariani G,Buccini P,Ferrari A,Catricala C

    更新日期:2006-12-01 00:00:00

  • Blood DNA methylation, nevi number, and the risk of melanoma.

    abstract::Germline mutations determining increased cutaneous malignant melanoma (CMM) risk have been identified in familial and sporadic CMM cases, but they account only for a small proportion of CMM cases. Recent evidence suggests that germline epimutations (e.g. DNA methylation alterations), which can be inherited similarly t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000112

    authors: Pergoli L,Favero C,Pfeiffer RM,Tarantini L,Calista D,Cavalleri T,Angelici L,Consonni D,Bertazzi PA,Pesatori AC,Landi MT,Bollati V

    更新日期:2014-10-01 00:00:00

  • Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

    abstract::Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499 patients treated with nivolumab or pembrolizumab. Seventy-three pati...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000705

    authors: Cybulska-Stopa B,Ziętek M,Kamińska-Winciorek G,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Zemełka T,Kubiatowski T,Suwiński R,Mackiewicz J,Rutkowski P

    更新日期:2021-02-01 00:00:00

  • Tyrosinase transfection produces melanin synthesis and growth retardation in glioma cells.

    abstract::Tyrosinase is the key enzyme in melanin biosynthesis in pigmented cells. We transfected 9L rat glioma cells with human tyrosinase cDNA that had been cloned in a high expression vector. Stable transfectants were selected by their resistance to the antibiotic G418. More than a dozen G418-resistant clones were isolated a...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199812000-00003

    authors: Singh MV,Jimbow K

    更新日期:1998-12-01 00:00:00

  • Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.

    abstract::Glutathione (GSH) is the major non-protein thiol in cells that plays a critical role against damage from electrophilic agents such as alkylating drugs. Selective therapeutic GSH elevation in normal but not in tumour cells has been suggested as a means of protecting host tissues against more intense doses of chemothera...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: del Olmo M,Alonso-Varona A,Castro B,Calle Y,Bilbao P,Palomares T

    更新日期:2000-04-01 00:00:00

  • Selective incorporation of the prototype melanoma seeker thiourea into nascent melanin: a chemical insight.

    abstract::The mechanism of selective incorporation of thiourea into melanotic melanoma was investigated by model experiments in which the effect of the compound was examined at various stages of melanogenesis in vitro. Up to 50% inhibition of dopachrome formation was observed in the tyrosinase-dopa reaction in the presence of t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199712000-00006

    authors: Palumbo A,Mårs U,De Martino L,d'Ischia M,Napolitano A,Larsson BS,Prota G

    更新日期:1997-12-01 00:00:00